Krystal Biotech, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2021-01-04

Reporting Person: Mason Christopher (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-04	Stock Option (Right to Buy)	$59.42	A	13600	Acquired	2031-01-04	Common Stock (13600)	Direct

Footnotes

F1: The options were awarded on January 4, 2021 and vest in equal amounts over 36 months.